Test Price
13,000 AED✅ Home Collection Available
OncoPro NCCN Lung Cancer Panel in UAE – Precision Genomic Profiling
Executive Summary & Core Metrics
Clinical Performance & Service Guarantees
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Next-Generation Sequencing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic post-test clinical guidance in result interpretation by a Specialist Diagnostic Radiologist.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
- Turnaround Time: 35 working days from sample receipt to comprehensive clinical report.
- Price: 13,000 AED (all-inclusive with no hidden charges).
Test Overview & Methodology
The OncoPro NCCN Lung Cancer Panel is a comprehensive next-generation sequencing (NGS) test that profiles genomic alterations in lung cancer, directly aligned with the latest NCCN guidelines for targeted therapy selection. The panel simultaneously analyzes 15+ NCCN-recommended genes including EGFR, ALK, ROS1, BRAF, KRAS, MET, RET, HER2, NTRK1/2/3, PIK3CA, FGFR1/2/3, PDGFRA, KIT, and DDR2. Methodology combines high-sensitivity NGS with advanced bioinformatic interpretation of calculated indices and derived ratios, delivering clinically actionable results in 35 working days.
| Feature | Our Test (OncoPro NCCN Panel) | Closest Alternative |
|---|---|---|
| Diagnostic Precision | NGS with ≥99.9% sensitivity; simultaneous analysis of 15+ NCCN‑recommended genes | Single‑gene PCR or limited hotspot panels |
| Methodology | Next Generation Sequencing (NGS) + Advanced Bioinformatics (Calculated Indices, Derived Ratios) | Standard NGS without deep integrative analytics |
| Turnaround & Reporting | 35 Working Days with clinical interpretation report including drug-sensitivity annotations | 45–60 days, often raw variant lists only |
| Clinical Guidance | Telephonic post-test session with clinical specialist | Not included or limited email support |
| Sample Type | 20 mL whole blood in two Streck tubes (18–22°C transport) | Tissue biopsy required for most alternatives |
Physician Insight & Safety Protocols
“As a Specialist Diagnostic Radiologist, I affirm that the OncoPro NCCN Lung Cancer Panel provides critical genomic intelligence for precision oncology. However, these findings must always be contextualized within the patient’s full clinical picture, imaging studies, and multidisciplinary team evaluation. The report delivers drug-sensitivity annotations and biomarker correlations, but treatment decisions should never be made from genomic data alone. Always consult with your treating oncologist before making any changes to your therapy.”
— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011
Advisory on Medication Continuity
⚠️ Do not discontinue prescribed medication without consulting your doctor.
Genomic test results may suggest alternative therapies, but you must never stop or modify your current treatment regimen without explicit guidance from your primary oncologist. Abrupt discontinuation can lead to disease progression or adverse events.
Safety Exclusion & Emergency Red Flags
Exclusion Criteria
- Known platelet disorders or coagulopathy (INR > 1.5).
- Severe anemia (hemoglobin < 8 g/dL).
- Active haemolysis or haemolytic crisis.
- Inability to provide informed consent due to cognitive impairment or language barrier without translator.
Emergency Red Flags
- Severe shortness of breath or chest pain after blood collection.
- Sudden confusion or loss of consciousness.
- Uncontrolled bleeding from venipuncture site lasting more than 10 minutes.
- Signs of allergic reaction (hives, wheezing, facial swelling).
If any of these symptoms occur, seek immediate emergency medical care or call 998/999.
Patient FAQ & Clinical Guidance
1. What is the OncoPro NCCN Lung Cancer Panel and why is it recommended?
The OncoPro NCCN Lung Cancer Panel is a comprehensive NGS-based genomic test that interrogates 15+ genes recommended by the National Comprehensive Cancer Network (NCCN) for lung cancer. It detects actionable mutations in EGFR, ALK, ROS1, BRAF, KRAS, MET, RET, HER2, NTRK, PIK3CA, FGFR, PDGFRA, KIT, and DDR2. The panel also provides calculated indices and derived ratios for tumor mutational burden (TMB) and microsatellite instability (MSI) assessment, all processed under ISO 9001:2015 accredited protocols with 99.9% diagnostic sensitivity. Results are delivered in 35 working days with a clinical interpretation report.
2. How do I prepare for the OncoPro panel and what is the collection process?
A 20 mL whole blood sample collected in two Streck tubes, transported at a strict 18–22°C – never refrigerated or frozen. Our VIP Mobile Phlebotomy service visits your home or office within a 30 km radius of Dubai Healthcare City. The phlebotomist brings a pre-assembled Streck tube kit with temperature-monitored packaging. A duly completed OncoPro Liquid Biopsy Clinical Information Form (Form 32) is mandatory. The sample is hand-delivered to our ISO-certified laboratory within 4 hours of collection for immediate processing. No fasting is required, and most medications do not interfere with the assay – however, please inform our team of any anticoagulant therapy.
3. When will I receive my results and what will the report contain?
Your comprehensive report is issued within 35 working days from sample receipt. The report includes: (a) a complete list of detected genomic variants with allele frequencies, (b) drug-sensitivity annotations tiered according to NCCN evidence levels, (c) tumor mutational burden (TMB) score and MSI status, (d) clinically relevant calculated indices and derived ratios, and (e) a clinical interpretation summary with therapeutic recommendations. A telephonic post-test guidance session with a clinical specialist is scheduled within 3 business days of report delivery to help you understand the findings in the context of your overall treatment plan.
4. Is this test covered by insurance in the UAE?
Most comprehensive health insurance plans in the UAE provide partial or full coverage for NCCN-recommended genomic profiling when ordered by an oncologist. Our team verifies your coverage directly with your insurer via WhatsApp at +971 54 548 8731 within 1 business day of booking. If your plan does not cover the test, we offer a transparent self-pay rate of 13,000 AED with a 10% discount for upfront full payment. A detailed receipt and medical report are provided for insurance reimbursement claims.
5. What makes this panel different from standard lung cancer genetic tests?
This panel goes beyond simple variant detection by providing calculated indices and derived ratios that inform tumor biology and treatment response prediction. Standard tests often report isolated mutations without integrative interpretation. Our panel delivers: (a) simultaneous profiling of all NCCN-recommended genes in a single assay, (b) TMB and MSI calculations from the same NGS run, (c) drug-gene interaction annotations with NCCN evidence levels, and (d) a dedicated telephonic guidance session. The liquid biopsy format also avoids the risks and delays of tissue biopsy, making it accessible to patients who are not candidates for surgical biopsy.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance & Patient Data Governance
- Data Protection: All patient genomic and clinical data are processed in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL). Data encryption, access controls, and audit trails are enforced at every stage.
- Health Information Governance: Adherence to Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields for secure electronic health record handling.
- Clinical Safety & Consent: All testing and sample collection procedures follow Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring informed consent, patient safety, and professional accountability.
- Accreditation: Laboratory processes are ISO 9001:2015 certified and aligned with College of American Pathologists (CAP) quality standards.
- DHA Licensing: The laboratory operates under DHA Facility License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE.
Clinical & Logistical Metadata
| Test Name | OncoPro NCCN Lung Cancer Panel |
| Price (AED) | 13,000 AED |
| Turnaround Time | 35 Working Days |
| Sample Type / Matrix | 20 mL Whole Blood in Streck Tubes (18–22°C transport; VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection) |
| Methodology Used | Next-Generation Sequencing (NGS) + Bioinformatic Calculation of Indices & Derived Ratios |
| ICD-10-CM Code | C34.9 (Malignant neoplasm of unspecified part of bronchus or lung), Z85.1 (Personal history of malignant neoplasm of bronchus and lung) |
| LOINC Code | 96984-7 (NGS panel for lung cancer – whole blood) |
| DHA Facility License & Laboratory Address | DHA Facility License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians